期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 64, 期 6, 页码 3249-3281出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.0c02156
关键词
-
This study successfully reduced the genotoxicity risk of GSK046 by replacing the acetamide functionality with a heterocyclic ring, and identified potent, selective, and bioavailable compounds through a structure-based drug design approach.
A number of reports have recently been published describing the discovery and optimization of bromo and extraterminal inhibitors which are selective for the second bromodomain (BD2); these include our own work toward GSK046 (3) and GSK620 (5). This paper describes our approach to mitigating the genotoxicity risk of GSK046 by replacement of the acetamide functionality with a heterocyclic ring. This was followed by a template-hopping and hybridization approach, guided by structurebased drug design, to incorporate learnings from other BD2-selective series, optimize the vector for the amide region, and explore the ZA cleft, leading to the identification of potent, selective, and bioavailable compounds 28 (GSK452), 39 (GSK737), and 36 (GSK217).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据